Market Research and Intelligences’ Post

𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐒𝐲𝐬𝐭𝐞𝐦𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐢𝐳𝐞, 𝐒𝐡𝐚𝐫𝐞 & 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 ➤ 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲: https://lnkd.in/eRnHfMCA A drug delivery system is a device designed to introduce a drug into the body while enhancing its efficacy and safety by controlling the dosage form, timing, and location of release. These systems include devices like auto-injectors, jet-injectors, and syringes. Manufacturers of drug delivery systems supply their products to pharmaceutical companies or directly to consumers through various distribution channels, including retail pharmacies, hospital pharmacies, and online pharmacies. ➤ 𝗕𝘆 𝗧𝘆𝗽𝗲: Inhalation, Transdermal, Injectable, and Others ➤𝗕𝘆 𝗗𝗲𝘃𝗶𝗰𝗲 𝗧𝘆𝗽𝗲: Conventional and Advanced ➤𝗕𝘆 𝗗𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻 𝗖𝗵𝗮𝗻𝗻𝗲𝗹: Hospital Pharmacies, Retail Pharmacies, and Others ➤ 𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Gerresheimer, BD, Kindeva Drug Delivery, Baxter International Inc., West Pharmaceutical Services, Ypsomed AG, Medtronic, NEMARA, E3D Elcam Drug Delivery Devices #DrugDeliverySystems #Pharmaceuticals #DrugDeliveryMarket #Biotechnology #HealthcareInnovation #MedicalDevices #Nanomedicine #TargetedTherapy #PharmaTech #HealthcareMarket #DrugDevelopment #Biopharma #DrugDeliveryResearch #MedicalInnovation #PharmaIndustry #DrugFormulation #DrugDeliveryTechnologies #MarketTrends #PharmaceuticalMarket #HealthcareResearch

𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐒𝐲𝐬𝐭𝐞𝐦𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐢𝐳𝐞, 𝐒𝐡𝐚𝐫𝐞 & 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 ➤ 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲: https://lnkd.in/gP8e4HTp A drug delivery system is a device designed to administer medication into the body, enhancing its effectiveness and safety by managing the dosage form, timing, and location of drug release. These systems include auto-injectors, jet-injectors, and syringes. Manufacturers distribute their products to pharmaceutical companies or consumers through various outlets, including retail pharmacies, hospital pharmacies, and online pharmacies. ➤ 𝗕𝘆 𝗧𝘆𝗽𝗲: Inhalation, Transdermal, Injectable, and Others ➤𝗕𝘆 𝗗𝗲𝘃𝗶𝗰𝗲 𝗧𝘆𝗽𝗲: Conventional and Advanced ➤𝗕𝘆 𝗗𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻 𝗖𝗵𝗮𝗻𝗻𝗲𝗹: Hospital Pharmacies, Retail Pharmacies, and Others ➤ 𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Gerresheimer, BD, Kindeva Drug Delivery, Baxter International Inc., West Pharmaceutical Services, Ypsomed AG, Medtronic, NEMARA, E3D Elcam Drug Delivery Devices #DrugDeliverySystems #Pharmaceuticals #DrugDelivery #DDS #HealthcareInnovation #DrugDeliveryTechnology #PharmaMarket #MedicalDevices #Biotechnology #ControlledRelease #Nanomedicine #MedicationManagement #DrugRelease #PharmaTech #DrugDeliveryMarket #ClinicalTrials #PharmaInnovation #DrugFormulation #AdvancedDrugDelivery #HealthTech

With 30 years of experience in the development and production of highly potent compounds, we are able to support your project from clinical through commercialization. Our API facilities can scale-up from laboratory-scale to 12,000 L vessels. The Oral Solid Dosage Drug Product manufacturing capabilities start with 100 g of blend and gradually increase according to the demand of your project, and we can even address #bioavailability-challenged APIs with enabling technologies such as spray drying, hot melt extrusion, micronization,and nanomilling. Our clinical and commercial injectable Drug Product facility can aseptically manufacture highly potent solutions in vials. This continuum of capabilities from #APIs to finished dosage Drug Products, including ready for-market packaging, labeling and serialization, allows you to either pick and choose your required services, or take advantage of our Integrated Supply Chain from development to commercialization. The level of integration is flexible and customizable, resulting in reduced complexity, de-risked supply chain and shorter lead-times. Read more about our services for Highly Potent & Oncology products: https://lnkd.in/ekPYiREv #cordenpharma #cdmo #highlypotent #oncology #pharma #pharmaindustry #pharmaceutical #oralsoliddosage

🌐 rizochem.com | rizochem.ae Pharma companies bet on flagship products to grow in strength Indian drug manufacturers are utilizing flagship products or "mother brands" to introduce new combinations and establish leadership in therapy areas, as per research by Pharmarack. For example, USV's anti-diabetes drug Glycomet has bolstered the company's reputation in diabetic therapy and facilitated partnerships with multinational drugmakers for innovative therapies. #trendingtopic #todaynews #newsmallbusiness #newsdaily #trendingearrings #newscarf #newshot #newsmedia #trendingnow🔥 #newscents #trendinginsta #pharmacymemes #newsheadlines #pharmacien #pharmazie #pharmacognosy #pharmaceris #pharmaindustry #trendingfacts #trendingnew #viralpost #daily_news #rizochempharmaceutical

New Article: Pens & Autoinjectors by William Welch, Executive Director of Market Development, shares his thoughts in the Drug Development & Delivery Special Report on Injection Devices. "Clients are thinking about their drug device strategy earlier in the development process. Many biophar­maceutical companies invest in research and development to not only en­hance device features and compatibility with a diverse range of large and small molecule drug products but also introduc­ing and evaluate them as viable dosage forms earlier in clinical trials through par­allel development strategies." Meeting the exponential growth in the development and use of autoinjectors, PCI Pharma Services continues to invest in device-agnostic, in­novative, scalable, injectable drug device final assembly, packaging, and la­beling technologies for autoinjectors, pre­filled syringes, PFS with needle safety device, pens, and on-body injector (OBIs).  "We have the scalability to handle the dynamic volumes of biopharmaceutical therapies, whether large or small, from early phase clinical trials through to com­mercial supply of niche personalized medicines to large, annual volume treatments." Read the complete Drug Development & Delivery special feature highlighting how the biopharmaceutical industry has made remarkable strides in developing patient-centric injectable devices that minimize pain, ensure precise drug delivery and reduce injection frequency, helping patients manage chronic diseases. https://lnkd.in/etNW9hVn #AdvancedDrugDelivery #PatientCentricity #CDMO #LetsTalkFuture

Market insights! Did you know that transdermal drug delivery is transforming how we administer medications? By delivering drugs directly through the skin and into the bloodstream, this method offers significant advantages over oral or intravenous administration. 🩹✨ According to GlobalData, over 250 companies are at the forefront of transdermal drug delivery innovation. These range from established pharmaceutical giants to promising startups, all driving the future of non-invasive therapy with groundbreaking technologies and formulations. The increasing number of patent applications in this sector highlights the significant potential and impact across various applications and regions. 🚀🔬 At Amarin, we're proud to be part of this innovative wave, developing cutting-edge transdermal systems that improve patient outcomes and comfort. Explore the future of medication delivery with us! 🌍💊 #TransdermalPatches #MedicalInnovation #PatientCare #Pharmaceuticals #AmarinTech #AmarinLegacy #InnovativeHealthcare #PharmaceuticalExcellence #Technology #TDS #transdermalsystem

Drug interchangeability and biosimilars are critical for improving access to biologic therapies and reducing healthcare costs. Interchangeable biosimilars are biologic medical products highly similar to an already approved reference product. The global market for biosimilars is expanding rapidly due to the increasing demand for cost-effective treatments and the patent expirations of major biologics.   Key players globally include Pfizer, Amgen, Novartis (through Sandoz), and Samsung Bioepis. In India, major companies include Biocon, Dr. Reddy's Laboratories, and Cipla. The approval process for biosimilars involves rigorous clinical trials to demonstrate similarity to the reference product, and the regulatory frameworks vary by region. In the U.S., the FDA has established a pathway for biosimilars, requiring extensive data to ensure similarity and safety. The FDA supports biosimilars as a means to enhance competition and lower drug prices. The European Medicines Agency (EMA) has a similar but slightly different process.   Opportunities in this sector include the potential for significant cost savings and expanded access to treatments. However, challenges include complex manufacturing processes, regulatory hurdles, and market acceptance. As biosimilars continue to evolve, they promise to play an integral role in global healthcare systems, but achieving their full potential requires overcoming these hurdles.   #DrugInterchangeability #Biosimilars #PharmacyLevelSubstitution #MajorPlayers #ApprovalProcess #ApprovedProducts #Koncepo

Understanding RLD vs. Generics: What's the Difference? 🤔 In the world of pharmaceuticals, it's crucial to distinguish between Reference Listed Drugs (RLD) and generics. RLDs are the original, FDA-approved drugs that set the standard for quality, safety, and efficacy. These pioneering drugs undergo rigorous testing and clinical trials to establish their therapeutic benefits, serving as a benchmark for all subsequent versions. Generics, on the other hand, are equivalent versions that enter the market once the patent of the RLD expires. They offer the same therapeutic benefits, strength, dosage form, and route of administration as their RLD counterparts but at a significantly lower cost. This affordability is due to the reduced financial burden of not having to repeat the extensive clinical trials conducted by the original manufacturers. Instead, generics must demonstrate bioequivalence, ensuring they work in the same way and provide the same clinical benefit. Here are some key benefits of generics: Cost-Effectiveness: Generics provide more affordable treatment options, making healthcare accessible to a broader population. 💰 Quality Assurance: Generic drugs are required to meet the same rigorous standards as RLDs in terms of safety, efficacy, and quality. 🔬 Therapeutic Equivalence: Generics are bioequivalent to RLDs, ensuring patients receive the same therapeutic effect. 🩺 At Amarin, we specialize in developing high-quality generic versions of transdermal and topical brand products. Our commitment to excellence ensures that our generics meet the stringent standards set by their RLD counterparts, providing patients with safe, effective, and affordable treatment options. Have questions about RLDs and generics? Email us at info@amarintech.com.ar. We're here to help! 📩 #AmarinTech #PharmaIndustry #GenericsVsRLD #HealthcareInnovation #AffordableMedicine #PatientCare #QualityCommitment #Pharmaceuticals #TDDS

🌟 Key Insights from the FDA’s Webinar on M13A Guidance Implementation 🌟 M13A Guidance, marking a significant step in harmonizing Bioequivalence (BE) standards for immediate-release solid oral dosage forms. This advancement simplifies global drug development and enhances patient access to affordable generics. 🔍 Major Takeaways: ▪️ Harmonization of BE Requirements: The first globally harmonized guideline focuses on BE assessment for immediate-release oral drugs. Aims to reduce disparities in regulatory requirements across regions. ▪️ Streamlined Requirements: Shift from requiring both fasting and fed BE studies for non-high-risk drugs to just one study. High-risk drugs still require both fasting and fed studies due to formulation complexities. ▪️ Risk-Based Approach: High-risk products are evaluated with stricter BE study conditions. Non-high-risk products benefit from simplified processes, significantly reducing costs. ▪️ FDA’s Implementation Impact: Updated 814 Product-Specific Guidances (PSGs) in October 2024 to align with M13A. Estimated annual cost savings of $50M for the industry. ▪️ Flexibility in Approaches: Alternative methods like physiologically based pharmacokinetic (PBPK) modeling and biowaivers are considered with scientific justification. Streamlined pathways for ANDA applicants to consult FDA for tailored guidance. 📈 Broader Implications: 🔆 Supports global drug harmonization and reduces duplicative studies, saving time and resources. 🔆 Encourages innovation while ensuring safety and efficacy in generic drug development. 🔆 Reflects the FDA’s commitment to facilitating access to high-quality medications. Let’s embrace this harmonized approach to advance patient care and drug development globally! 🌍💊 #Bioequivalence #GenericDrugs #RegulatoryAffairs #ClinicalResearch #ANDA #USFDA